discontinue sulfonylurea when starting glp-1 receptor agonist GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies | Cardiovascular Drugs and Therapy Switching Between Glucagon-Like Peptide-1 Receptor

Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ

However, the degree of HbA1c lowering desired must be taken into account, and the relatively modest glycemic effects at lower starting HbA1c, as well as their cost compared to other agents may temper ones enthusiasm for prescribing this class of therapy

At the same time, Camilleri pointed out that the gastric slowing is also related to the benefits of the drug

So ideally, someone is seen in a clinical setting with long-term follow up

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis

Anazco D, Fansa S, Hurtado MD, et al